A strategy that analyzes the structural properties of RNA could help identify regions that are promising targets for antiviral drugs.

The SAIR database is designed to help scientists train AI models to better predict protein-ligand binding affinities for drug ...

Donanemab was licensed for use in the UK last year but is still only available privately as it was not deemed to be cost-effective enough to be subsidised by the National Health System (NHS).

A team of researchers at the University of California, Davis, made small tweaks to the molecular structure of lysergic acid diethylamide (LSD) to see if it could be turned into an effective brain ...

Donanemab, recently approved by the FDA, offers new hope for patients in the early stages of Alzheimer’s disease—slowing memory loss by up to 29% over 18 months (1 Trusted Source ...

Writing in Nature, Wu et al. 1 report a groundbreaking method for determining previously elusive molecular structures. The researchers developed a crystalline porous material containing molecular ...

Treatment with donanemab (Kisunla) raised the risk of amyloid-related imaging abnormalities (ARIA) in people with early symptomatic Alzheimer's disease, a secondary analysis of trial data showed ...

Eli Lilly and Company (NYSE: LLY) today announced that the National Medical Products Administration (NMPA) in China has approved Kisunla™ (donanemab-azbt, 350 mg/20 mL every four weeks injection ...

Trailblazer-Alz6 enrolled 843 people, randomized to one of four dosing arms. The first tested the standard protocol, in which participants received three monthly doses of 700 mg, then 1,400 mg monthly ...

ConspectusA century ago, German neurologist Alois Alzheimer documented the first case of Alzheimer’s disease (AD), illuminating cognitive impairments associated with the presence of abnormal protein ...

Donanemab is approved to treat adults in the early stages of Alzheimer’s disease who have one or no copies of the apolipoprotein E4 gene (ApoE4). A person can have no copies, one copy or two of ...

The drug Donanemab has been found to slow the progression of Alzheimer ’s disease. Despite this is has been rejected for widespread use in the health service in England after the health spending ...